secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001104659-25-096920
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma appoints John Leaman as independent director, formalizes CEO and CFO titles
--------------------------------------------------------------------------------

- John Leaman, MD appointed independent director effective Oct 1, 2025; joins Audit Committee.
- Interim titles removed: Iain Dukes now CEO, Charles Parker now CFO of Traws Pharma.
- Dr. Leaman brings experience as CFO of Cellarity, Impel Pharma, Selecta Biosciences.
- Company progressing Phase 2 studies for lead candidate ratutrelvir (COVID-19 treatment).
- CFO Charles Parker compensated via Stout at $500/hr, up to $50k/month for services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925096920/0001104659-25-096920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925096920/tm2528048d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-096920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer